Basic Information

918 Deming Way, STE 100
MADISON, WI, 53717-1945

Company Profile


Additional Details

Field Value
DUNS: 787342471
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a

  1. A Novel Antibody Drug Conjugate for Metastatic Renal Cancer Treatment

    Amount: $224,734.00

    Project Summary The incidence of renal cell cancer has been rising steadily and for those that have tumor recurrence after surgery, the prognosis is generally poor. In 2013 an estimated 65,150 new cas ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. SBIR Phase I: Development of a High Throughput Glycosyl-Scanning Platform

    Amount: $150,000.00

    This Small Business Innovation Research Phase I project highlights a strategy for the development of the first integrated high throughput pipeline to synthesize and evaluate novel sugar-drug conjugate ...

    SBIR Phase I 2011 National Science Foundation
  3. A new paradigm for antibody-directed conjugates

    Amount: $199,122.00

    DESCRIPTION (provided by applicant): Non-small cell lung cancer (NSCLC) is among the most common and lethal cancers yet, the current standard of care for advanced stage NSCLC provides only modest imp ...

    SBIR Phase I 2011 Department of Health and Human Services
  4. Amphotericin B Analogs

    Amount: $277,253.00

    DESCRIPTION (provided by applicant): Current antifungal therapy is limited by the types of drugs available to treat systemic infections due to emerging and comparatively rare fungi different from the ...

    SBIR Phase I 2009 Department of Health and Human Services
  5. STTR Phase I: Development of Bacterial Glycorandomization Hosts

    Amount: $75,000.00

    This Small Business Technology Transfer Research Phase I project develops methodology needed for the production of sugar enhanced (glycosidic) compound libraries and final therapeutic leads. Sugar att ...

    STTR Phase I 2008 National Science Foundation
  6. Automation of Neoglycoside Synthesis

    Amount: $198,836.00

    DESCRIPTION (provided by applicant): The process of small molecule and natural product glycorandomization developed by Thorson and coworkers has been validated as one of the first simple, efficient an ...

    SBIR Phase I 2008 Department of Health and Human Services
  7. novel macrolides as anti-infective drugs

    Amount: $244,089.00

    DESCRIPTION (provided by applicant): Although it has long been known that macrolide glycosylation is absolutely essential for antibacterial activity, the megalomicins (which differ from erythromycins ...

    SBIR Phase I 2007 Department of Health and Human Services
  8. cardiac neoglycosides as cancer drugs

    Amount: $163,192.00

    DESCRIPTION (provided by applicant): Epidemiological evidence points to the value of cardiac glycosides like digoxin and digitoxin for treatment of breast cancer and recent reports suggest they may be ...

    SBIR Phase I 2007 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government